Last updated: July 16, 2026
Nippon Shinyaku v. Sarepta 1:21-cv-01015-GBW Litigation Summary and Patent Analysis
Executive summary: In Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc., case number 1:21-cv-01015-GBW (District of Delaware; Judge George B. Woods), Nippon Shinyaku sued Sarepta in 2021 over U.S. patent rights tied to Sarepta’s DMD therapeutic portfolio. The litigation is aligned with the common IP risk profile in Duchenne muscular dystrophy (DMD) drug ecosystems: a plaintiff challenges whether a competitor’s products, methods, or manufacturing steps infringe one or more Orange Book-linked or non-Orange Book patents. Key case posture and outcomes cannot be accurately summarized here because the record required to extract the asserted patent numbers, claims, procedural milestones, claim construction rulings, and final disposition is not available in the provided input.
Litigation summary (data required for accuracy is missing):
No patent numbers asserted, no asserted claims, no DMF/ANDA/BLA linkage, no infringement/non-infringement/invalidity theories, no Markman orders, no dispositive motion outcomes, and no final judgment or settlement terms are included in the prompt. Without those specifics, any detailed litigation narrative or claim-by-claim analysis would risk being wrong.
Case identification (given):
- Court: U.S. District Court for the District of Delaware
- Case: 1:21-cv-01015-GBW
- Judge: George B. Woods (GBW)
- Parties: Nippon Shinyaku Co., Ltd. (plaintiff) vs. Sarepta Therapeutics, Inc. (defendant)
What patents were asserted in Nippon Shinyaku v. Sarepta 1:21-cv-01015-GBW?
Answer (required facts not provided): The asserted U.S. patent numbers and their assigned invention titles are not present in the input. A correct summary must list each asserted patent, its expiration schedule, and the specific claims alleged to be infringed.
Which patent estate components typically drive these DMD disputes?
In DMD litigation involving Sarepta, the patent estate usually spans:
- Product composition/formulation patents (drug substance stability, excipients, dosing vehicle)
- Delivery system patents (AAV capsid variants, promoter/enhancer constructs, vector genome design)
- Method-of-use patents (patient selection, dosing regimens, immunomodulation, administration schedules)
- Manufacturing process patents (process steps affecting purity, aggregation control, vector potency)
- Regulatory linkage patents (often tied to Orange Book or licensing arrangements)
This case’s actual asserted categories cannot be confirmed without the complaint and claim charts.
What is the procedural timeline for 1:21-cv-01015-GBW?
Answer (required facts not provided): The complaint filing date, answer, amended pleadings, scheduling order dates, Markman dates, and motion practice outcomes (12(b)(6), injunction motions, summary judgment, Daubert) are not provided.
Procedural milestones that determine leverage in these disputes
A Delaware case usually turns on:
- Markman claim construction outcomes narrowing infringement/invalidity pathways
- Infringement evidence (accused product composition, vectors, manufacturing records)
- Validity defenses (anticipation/obviousness based on prior art, written description enablement)
- Indefiniteness rulings
- Settlement timing relative to scheduled trial and expert disclosures
Those specifics cannot be extracted from the prompt.
What did Nippon Shinyaku allege Sarepta infringed?
Answer (required facts not provided): The input does not state:
- accused products (which Sarepta therapy and dosage form)
- infringement theory (direct infringement, inducement, contributory)
- specific methods or manufacturing steps alleged to infringe
- whether the case is tied to an approval pathway or competitive entry
How strong is Nippon Shinyaku’s patent case in this matter?
Answer (required facts not provided): Patent strength analysis requires:
- asserted patents and claims
- prosecution history and priority dates
- cited prior art
- claim construction outcomes
- infringement/invalidity briefing record
None are included.
What claim construction rulings affected infringement or invalidity?
Answer (required facts not provided): Markman rulings are decisive in Delaware. The input contains no claim construction orders or even the number of disputed terms.
Did the court grant any injunction, deny any injunction, or rule on preliminary relief?
Answer (required facts not provided): Injunctive relief requires a record of:
- preliminary injunction motion
- standard-of-review findings
- likelihood of success on merits
- irreparable harm and balance of hardships
- bond amount and duration
No such motion outcomes are provided.
What is the current status of 1:21-cv-01015-GBW?
Answer (required facts not provided): The prompt does not provide:
- whether the case is ongoing
- dismissal, consent judgment, or summary judgment disposition
- settlement agreement existence or effective dates
- post-judgment appeals (if any)
Did Sarepta challenge validity with prior art or §112 defenses?
Answer (required facts not provided): Validity challenges are claim-specific and depend on the asserted patents. The input provides no list of defenses asserted or prior art references.
How could this litigation affect biosimilar or generic entry risk for Sarepta competitors?
Answer (required facts not provided): Competitor risk depends on:
- which patents remain in force
- whether the court enjoined activities
- whether any patents were found invalid
- whether infringement was determined on key claims
- exclusivity and regulatory entry timing
No postures or outcomes are provided.
Key Takeaways
- The case is identified as Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc., 1:21-cv-01015-GBW in Delaware before Judge George B. Woods.
- A litigation summary that includes asserted patents, infringement allegations, claim construction, validity rulings, and outcome cannot be produced from the provided input.
- For business and legal planning, the controlling inputs are: the complaint’s asserted patent list, scheduled claim construction and dispositive motion outcomes, and the final disposition/settlement status. Those are not included here.
FAQs
- What patents did Nippon Shinyaku assert against Sarepta in 1:21-cv-01015-GBW?
- What infringement theories were pled (direct, inducement, contributory) in Nippon Shinyaku v. Sarepta?
- Did the Delaware court issue a Markman order that narrowed key claim terms in 1:21-cv-01015-GBW?
- Was the case resolved by settlement, dismissal, or judgment, and on what date?
- Which Sarepta DMD product or method-of-use was the focus of the accused infringement in this case?
References
No sources were provided in the prompt, and no docket or court document text was included to support citation.
